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Introduction: Current U.S. cardiology guidelines recommend oral anticoagulation (OAC) to reduce
stroke risk in selected patients with atrial fibrillation (AF), but no formal AF OAC recommendations
exist to guide emergency medicine clinicians in the acute care setting. We sought to characterize
emergency department (ED) OAC prescribing practices after an ED AF diagnosis.
Methods: This retrospective study included index visits for OAC-naive patients ≥18 years old who
were discharged home from the ED at an urban, academic, tertiary hospital with a primary diagnosis
of AF from 2012-2014. Five hypothesis-blinded, chart reviewers abstracted data from patient
problem lists and medical history in the electronic health record to assess stroke (CHA2DS2-VASc)
and bleeding risk (HAS-BLED). The primary outcome was the provision of an OAC prescription at
discharge in OAC-naive patients with high stroke risk. Descriptive statistics and multivariable logistic
regression assessed associations between OAC prescription and patient characteristics.
Results: We included 138 patient visits in our analysis, of whom 39.9% (n = 55) were low
stroke risk (CHA2DS2-VASc = 0 in males and 1 in females), 15.9% (n = 22) were intermediate
risk (CHA2DS2-VASc = 1 in males), and 44.2% (n = 61) were high risk (CHA2DS2-VASc ≥ 2). Of
patients with high stroke risk and low-to-intermediate bleeding risk (n = 57), 80.7% were not
prescribed an OAC at discharge. Cardiology consultation and female gender, but not stroke risk
(CHA2DS2-VASc score), were predictors of an ED provider prescribing an OAC to an OAC-naive
AF patient at ED discharge.
Conclusion: The majority of OAC-eligible patients were discharged home without an OAC
prescription. In OAC-naive patients discharged home from the ED, cardiology consultation and
female gender were associated with OAC prescription. Our findings suggest that access to expert
opinion may improve provider comfort with OAC prescribing and highlight the need for improved
guidelines specific to ED-management of AF. [West J Emerg Med. 2020;21(4)924–934.]
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INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia
presenting to emergency departments (EDs) and accounts
for more than 500,000 annual ED visits; up to one quarter
of all new AF diagnoses are made in the ED.1-2 The
related costs for these patients total more than $26 billion
annually.3 Importantly, AF has significant associated
morbidity and mortality,4 with a fivefold increase in an
individual’s lifetime risk of stroke when compared to a
non-AF reference population.5-7 Compared to estimates
from 2010, the prevalence and incidence of AF are both
expected to double by the year 2030, when over 12 million
Americans will be affected.8
Although studies show that oral anticoagulation (OAC)
therapy with traditional agents such as warfarin or nonvitamin K oral anticoagulants (NOACs) can reduce stroke
risk by 64% in non-valvular AF, providers hesitate to
prescribe OACs for reasons that include increased bleeding
risk.7,9-11 Professional guidelines recommend the use of
CHA2DS2-VASc, a validated scoring system that stratifies
patients’ annual stroke risk based on age, gender, and
comorbid conditions, and HAS-BLED, a complementary
scoring system that predicts the likelihood of a major
bleeding event in anticoagulated patients, to determine
appropriate OAC recommendations.12-15
Multiple studies show a net positive clinical benefit for
OAC prophylaxis in AF patients with at least one additional
risk factor for stroke.7,16-22 With rising pressure to decrease
unnecessary hospitalizations, up to 89% of patients with
new-onset AF may be discharged from the ED.17 ED
providers may defer OAC initiation for a patient with new
AF to an outpatient provider, but more than half of AF
patients discharged from the ED fail to achieve outpatient
follow-up within 90 days of hospital discharge.17,19 Thus,
ED management at discharge may determine the trajectory
of care and impact clinical outcomes.
The objective of this study was to describe baseline ED
OAC prescribing rates for eligible OAC-naive AF patients,
characterize predictors of OAC prescribing, and identify
variation from established guidelines and risk-stratification
tools. This information will inform future interventions
to improve prescribing in the ED and, ultimately, clinical
outcomes for AF patients.
METHODS
Study Design and Setting
This retrospective study took place at an academic,
tertiary care hospital ED with an affiliated emergency
medicine (EM) residency program staffed by 43 boardcertified faculty and EM residency-trained fellows with
an annual ED volume of 50,000 adult patients. The study
was approved by the Oregon Health & Science University
Institutional Review Board.
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Population Health Research Capsule
What do we already know about this issue?
Up to one quarter of all new atrial fibrillation (AF)
diagnoses are made in the emergency department
(ED), and AF accounts for more than 500,000
annual ED visits.
What was the research question?
What factors influence emergency physician oral
anticoagulant (OAC) prescription rates for patients
with a primary diagnosis of AF at home discharge?
What was the major finding of the study?
The majority of patients were not prescribed an
OAC. Cardiology consultation and female gender
were associated with OAC prescription.
How does this improve population health?
ED-specific guidelines and access to expert opinion
may improve time to OAC prescription for OACnaive AF and reduce the associated morbidity and
mortality.

Selection of Participants
A query of the electronic health record (EHR) identified
patients ≥ 18 years old who were evaluated in the ED between
January 1, 2012–December 31, 2014, and given a primary
diagnosis of AF (International Classification of Disease-9
code 427.31) and discharged home from the ED. We excluded
patients who were taking warfarin or a NOAC at the time of
presentation. Patients taking aspirin at the time of presentation
were considered OAC-naive, as aspirin is not recommended
for those at high risk for stroke.15 Only the first eligible visit
during the study period was included.
Data Collection and Processing
We collected patient data for all qualifying patient
encounters using the abstraction criteria described by Kaji et
al.23 Four chart abstractors blinded to the study hypotheses
performed the chart review. The principal investigator trained
each abstractor and provided them with standardized data
collection procedures and definitions. A random sample of
10 encounters was selected for re-abstraction to determine
inter-rater reliability. We assessed Fleiss’ kappa and intraclass
correlation statistics.
Study data were collected and managed using Research
Electronic Data Capture (REDCap) electronic data capture
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tools. REDCap is a secure, web-based application designed
to support data capture for research studies that is endorsed
for clinical research purposes by institutions including
Oregon Health & Science University.24 Abstracted data
included patient demographics, risk factors for stroke/
bleeding,12,15,25 other comorbidities documented within
one year of the ED encounter, substance use (alcohol,
tobacco, illicit drug use), current medication use (OACs,
antiplatelets, diuretics, heart rate-controlling medications),
and disabilities or trouble with activities of daily living
documented within the last year. Abstracted data related to
management in the ED included chief complaint at time of
presentation, arrhythmia management attempted in the ED,
provision of OAC/antiplatelet prescription or adjustment
to antiplatelet, specialty consultations obtained by the
ED provider and recommendations for anticoagulation,
reason from provider for management decisions, patient
disposition, and follow-up international normalized ratio
(INR) (if applicable). (See Appendix for further details of
data captured.)
Outcome Measure
The primary outcome was the provision of an OAC
prescription at home discharge in OAC-naive patients with
AF and a high stroke risk (CHA2DS2-VASc ≥ 2). OACs
included warfarin and NOACs (factor Xa and thrombin
inhibitors). Based on investigator consensus, we simplified
the indications for stroke prophylaxis to those who would
be most acceptable by ED providers: AF patients with high
stroke risk by CHA2DS2-VASc12 (scores ≥ 2) and low bleeding
risk by HAS-BLED25 (scores 0-2), where AF patients would
derive the greatest benefit and the least amount of harm from
an OAC prescription. Although a high HAS-BLED score
does not preclude the use of OACs, we chose to exclude them
from the OAC indicated cohort to simplify the analysis to the
most obvious cohort needing OACs with minimal concerns of
adverse events for the risk-averse emergency provider.
Variables
We identified predictor variables to compare patients
prescribed an OAC upon discharge from the ED to those
who were not prescribed an OAC. Variables were selected
based on the reviewed literature and factors thought to
impact clinical decision making, and included the following:
calculated CHA2DS2-VASc and HAS-BLED scores stratifed
into low, intermediate and high risk; health insurance; gender;
disabilities; cardiology consultation; return to normal sinus
rhythm at disposition; whether cardioversion was attempted in
the ED; and first method of rate or rhythm control attempted.
All were identified through review of the ED provider and
consultant notes as well as encounter registration data.
We also compared patients who received a cardiology
consult in the ED to those who did not in order to

Western Journal of Emergency Medicine

identify predictors of specialty consultation. Selected
variables included the following: duration of symptoms;
health insurance; and comorbidities used to calculate
the CHA2DS2-VASc score (congestive heart failure,
hypertension, age, diabetes, gender, stroke/transient
ischemic attack [TIA], vascular disease). For the patients
who received a cardiology consultation, we determined
whether cardiology’s recommendation regarding OAC
provision agreed with whether the emergency physician
prescribed an OAC and identified any documented reason
for discrepancy.
We documented whether or not the emergency physician
cited use of a clinical guideline (such as CHA2DS2-VASc or
HAS-BLED) in his or her clinical decision-making process.
Similarly, we identified emergency physicians’ reasons for
lack of OAC prescription in OAC-eligible patients. Lastly, we
evaluated OAC and NOAC prescribing trends to investigate
whether physician familiarity with newer drugs influenced
prescribing of an anticoagulant.
Statistical Analysis
Descriptive statistics were used to summarize age, race,
ethnicity, insurance, the reason for evaluation, medications
at the time of the encounter, CHADS2 score, CHA2DS2VASc score, HAS-BLED score, and follow-up instructions.
We used multivariable logistic regression to identify
factors associated with provision of OAC prescription at
ED discharge and also to identify factors associated with
cardiology consultation. Model diagnostics were visually
inspected for outliers and leverage values. All tests were
two-sided with a significance level of 0.05. The analysis was
conducted with SAS 9.4 (Cary, NC, USA).
RESULTS
Characteristics of Study Subjects
During the study period, 317 patients were identified, with
138 ultimately meeting inclusion criteria (Figure 1). Their
baseline characteristics are reported in Table 1.
Their mean age was 59 years, 39.1% were female,
and 39.9% had no history of AF. Overall, 39.9% (n = 55)
were low risk for stroke (CHA2DS2-VASc = 0 in males
and 1 in females), 15.9% (n = 22) were intermediate risk
(CHA2DS2-VASc = 1 in males), and 44.2% (n = 61) were
high risk (CHA2DS2-VASc≥2)12 for stroke. About half
(49.3%) of included patients were taking aspirin at the time
of presentation.
Main Results
Among the 138 OAC-naive patient-visits, 14.5% (n = 20)
received a new prescription of warfarin or NOAC at discharge
for stroke prophylaxis (Table 1). Other medications were not
included in the analyses, but usage is detailed in Appendix
Table A1.
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317 patient encounters
with a primary diagnosis
of AF identified

Excluded 57 repeat
patient encounters

260 index encounters
for a primary diagnosis
of AF included

Excluded 82 patients
because patient was
admitted, transferred,
died in ED, or had
unknown disposition

178 patients discharged
from the ED included

Excluded 40 patients for
current OAC/NOAC use

138 patients included in
final analysis

Figure 1. Cohort selection of patients with atrial fibrillation.
AF, atrial fibrillation; ED, emergency department; OAC, oral anticoagulant; NOAC, non-vitamin K oral anticoagulants.

Provision of an Oral Anticoagulant Prescription Stratified By
OAC-Naive Patients’ CHA2DS2-VASc and HAS-BLED Scores
OAC prescriptions were provided for 10.9% (n = 6)
of patients with low stroke risk (CHA2DS2-VASc = 0 in
males and 1 in females); 9.1% (n = 2) of patients with
intermediate stroke risk (CHA2DS2-VASc = 1 in males);
and 19.7% (n = 12) of patients with high stroke risk
(CHA2DS2-VASc≥2) (Table 2).
When stratified by HAS-BLED scores, OAC prescriptions
were provided for 12.4% (n = 10/81) of patients with low
bleeding risk, 22.6% (n = 7/31) of patients with intermediate
bleeding risk, and 11.5% (n = 3/26) of patients with high
bleeding risk. When stroke risk and bleeding risk were
considered together, we found that patients with a high stroke
Volume 21, no. 4: July 2020

risk and low bleeding risk (n = 13) were prescribed an OAC
15.4% (n = 2) of the time (Figure 2).
Among all those prescribed an OAC (any risk) (n =
20), 10.0% (n = 2) were at intermediate risk and 60.0%
(n = 12) were at high risk for stroke. Among those at low
risk of stroke (n = 55), 36.3% (n = 20) received aspirin and
10.9% (n = 6) received OACs. Of these low-risk patients
prescribed aspirin, 95.0% (n = 19) were in normal sinus
rhythm when they were discharged from the ED. Compared
to the intermediate and high stroke risk patients who
received an OAC prescription, we found that the low stroke
risk patients prescribed an OAC were more likely to be
younger (49.6 years vs 58.7 years), to be female (83% vs
57% male), to have private or commercial insurance (67%
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Table 1. Patient characteristics and calculated stroke and bleeding risk scores for 138 OAC-naive atrial fibrillation patients who were
discharged home from the ED.
Characteristic (n, %)
Overall (n=138,100%) OAC Prescription (n=20,14.5%) No OAC (n=118,85.5%) p-value*
Age (years), mean (SD)

58.7 (17.1)

61.4 (13.8)

58.2 (17.6)

0.69

Female gender

54 (39.1%)

13 (65.0%)

41 (34.7%)

0.01

128 (92.8%)

20 (100.0%)

108 (91.5%)

1.00

Black or African American

3 (2.2%)

0 (0.0%)

3 (2.5%)

Asian or Pacific Islander

2 (1.4%)

0 (0.0%)

2 (1.7%)

Other

2 (1.4%)

0 (0.0%)

2 (1.7%)

Not reported

3 (2.2%)

0 (0.0%)

3 (2.5%)

Commercial

59 (42.8%)

10 (50.0%)

49 (41.5%)

Medicare/Medicaid

64 (46.4%)

10 (50.0%)

54 (45.8%)

Other

15 (10.9%)

0 (0.0%)

15 (12.7%)

81 (58.7%)

10 (50.0%)

71 (60.2%)

0.29

< 6 hours

64 (46.4%)

11 (55.0%)

53 (44.9%)

0.05

6–48 hours

28 (20.3%)

3 (15.0%)

25 (21.2%)

> 48 hours

10 (7.2%)

4 (20.0%)

6 (5.1%)

Unknown

36 (26.1%)

2 (10.0%)

34 (28.8%)

Race
White

Insurance

History of AF

0.24

Symptom onset

Heart rate on arrival, mean (SD)

118 (31.5)

112 (30.3)

119 (31.7)

Rate-controlling medication PTA

63 (45.7%)

12 (60.0%)

51 (43.2%)

0.16

On aspirin prior to presentation

68 (49.3%)

12 (60.0%)

56 (47.5%)

0.30

Low stroke risk

55 (39.9%)

6 (30.0%)

49 (41.5%)

0.30

Intermediate stroke risk

22 (15.9%)

2 (10.0%)

20 (16.9%)

High stroke risk

61 (44.2%)

12 (60.0%)

49 (41.5%)

Low bleeding risk

81 (58.7%)

10 (50.0%)

71 (60.2%)

Intermediate bleeding risk

31 (22.5%)

7 (35.0%)

24 (20.3%)

High bleeding risk

26 (18.8%)

3 (15.0%)

23 (19.5%)

0

57 (41.3%)

10 (50.0%)

47 (39.8%)

1

52 (37.7%)

4 (20.0%)

48 (40.7%)

2

21 (15.2%)

4 (20.0%)

17 (14.4%)

3

6 (4.3%)

1 (5.0%)

5 (4.2%)

4

2 (1.4%)

1 (5.0%)

1 (0.8%)

Rhythm

16 (11.6%)

1 (5.0%)

15 (12.7%)

Rate

65 (47.1%)

9 (45.0%)

56 (47.5%)

None

57 (41.3%)

10 (50.0%)

47 (39.8%)

CHA2DS2-VASc group

†

HAS-BLED group§
0.42

Number of methods of control attempted
0.19

First method of control
0.52

Cardioversion attempted
18 (13.0%)
4 (20.0%)
14 (11.9%)
0.30
*t-tests for continuous data, chi-square tests for categorical data, and Fisher’s exact tests for sparse categorical data.
†
CHA2DS2-VASc (congestive heart failure, hypertension, age≥75, diabetes mellitus, prior stroke or transient ischemic attack, gender, age
65-74 years, and vascular disease). 0 in males, 1 in females = low risk for stroke, 1 in males = intermediate risk, and ≥ 2 high risk.
§
HAS-BLED (hypertension, abnormal renal function or liver function, stroke, bleeding, labile international normalized ratio [excluded as all
patients not on warfarin prior to inclusion], elderly >85 years old, and drugs and alcohol): 0 = low risk, 1 to 2 = moderate risk, >2 = high risk.
OAC, oral anticoagulant; AF, atrial fibrillation; SD, standard deviation; PTA, prior to arrival.
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Table 2. Provision of OAC prescription by CHA2DS2-VASc and HAS-BLED score.
CHA2DS2-VASc score†

HAS-BLED score§

OAC Prescription
Yes (n=20)

No (n=118)

Total (n=138)

Low stroke risk
Low bleeding risk

6 (11.1%)

48 (88.9%)

54 (100%)

Intermediate bleeding risk

0 (0%)

1 (100%)

1 (100%)

High bleeding risk

0 (0%)

0 (0%)

0 (0%)

6

49

55

Total
Intermediate stroke risk
Low bleeding risk

2 (14.3%)

12 (85.7%)

14 (100%)

Intermediate bleeding risk

0 (0%)

5 (100%)

5 (100%)

High bleeding risk

0 (0%)

3 (100%)

3 (100%)

2

20

22

Low bleeding risk

2 (15.4%)

11 (84.6%)

13 (100%)

Intermediate bleeding risk

7 (28.0%)

18 (72.0%)

25 (100%)

High bleeding risk

3 (13.0%)

20 (87.0%)

23 (100%)

Total
High stroke risk

Total
12
49
61
CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, prior stroke or transient ischemic attack, gender, age
65-74 years, and vascular disease). 0 in males, 1 in females = low risk for stroke, 1 in males = intermediate risk, and ≥ 2 high risk.
§
HAS-BLED (hypertension, abnormal renal function or liver function, stroke, bleeding, labile international normalized ratio [excluded as all
patients not on warfarin prior to inclusion], elderly >85 years old, and drugs and alcohol): 0 = low risk, 1 to 2 = moderate risk, >2 = high risk.
OAC, oral anticoagulant; AF, atrial fibrillation.
†

vs 43%), to present with a higher heart rate on arrival (137
vs 112), and have a shorter duration of symptoms, to have
multiple methods of control attempted, to have cardioversion
attempted (50% vs 7%), and were less likely to be on aspirin
at the time of presentation (66.7% vs 33.3%).
Predictors of OAC Prescription
Multivariable logistic regression showed that cardiology
consultation and female gender were significant predictors
of prescribing (Table 3). Females had 2.9 (95% confidence
interval [CI], 1.0-8.5) times the odds of receiving an OAC
prescription as compared to males, and patients with a
cardiology consult had 12.5 (95% CI, 1.5-100.5) times the
odds of receving an OAC prescription as compared to patients
without a cardiology consult.
Predictors of Cardiology Consultation
Cardiology was consulted in 64.5% of all cases. We
identified hypertension as a significant predictor of cardiology
consultation after controlling for duration of symptoms,
insurance status, and comorbidities associated with CHA2DS2VASc score calculation (Appendix Table A2). Patients with a
diagnosis of hypertension had 2.7 (95% CI, 1.0-7.2) times the
odds of having a cardiology consult compared with patients
without hypertension.
Volume 21, no. 4: July 2020

Cardiologists’ Recommendations for Oral Anticoagulant
Prescription
For the 89 patients who received a cardiology
consultation, we examined whether cardiology’s
recommendation regarding OAC provision agreed with
whether the ED provider prescribed an OAC. Cardiology
recommended an OAC prescription for 10 (11.2%) patients,
recommended against an OAC prescription for 40 (45.0%)
patients, or opted to discuss OAC management at a later
time for 19 (21.3%) patients (Appendix Table A3). Their
recommendation was recorded as “unknown” for 20 (22.5%)
patients. Other recommendations made by cardiology
regarding patient management are specified in the appendix
(Appendix Table A3).
Agreement Between Cardiologists’ Recommendation for
OAC And ED Provider Prescribing Patterns
For the 89 patients who received a cardiology
consultation (36 of whom [40.5%] were high stroke risk),
there were 12 cases in which cardiology’s recommendation
was not congruent with the emergency physician’s decision
(Appendix Table A4).
Cardiology recommended an OAC prescription for 10 of
the 89 patients (11.2%), of whom seven were not prescribed an
OAC. Cardiology did not recommend an OAC be prescribed
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Low stroke risk, n=55
Low bleed risk, n=81
No OAC prescribed, n=118
OAC-naive patients, n=138

Intermediate stroke risk, n=22

Intermediate bleed risk, n=31
High stroke risk, n=61
High bleed risk, n=26

OAC prescribed, n=20

Figure 2. Patients who met exclusion criteria were stratified into low, intermediate, and high stroke risk by CHA2DS2-VASc score. They
were then further stratified into low, intermediate, and high bleed risk by HAS-BLED scores. Next, they were stratified by prescription of
oral anticoagulant (OAC) or not.

to 40 patients, although five (12.5%) of these patients were
prescribed an OAC by the emergency physician. We attempted
to identify reasons for these discrepancies within the patients’
charts and identified one instance in which the ED provider
opted against the recommended OAC prescription due to the
patient’s low stroke risk, and another in which the ED provider
prescribed an OAC after citing the patient’s high CHADS2 score
(Appendix Table A1). Interestingly, patients who did not receive
an OAC prescription despite cardiology’s recommendations
were more likely to have a high HAS-BLED score (2/7 patients
vs 0/5 patients who received an OAC prescription despite
cardiology’s recommendation).
Guidelines Cited by Provider
Of the 138 patient visits included, ED providers cited
use of a clinical guideline such as CHA2DS2-VASc or HASBLED in AF management in 20.3% (n = 28) of visits. Use
of a guideline was cited in 20.0% (n = 4) of visits where the
patient was given an OAC prescription, and in 31.2% (n =
24) of visits where the patient was not prescribed an OAC or
antiplatelet. Of all guidelines cited, CHADS2 was the most
cited guideline, both for or against an OAC prescription.
All patient visits were reviewed for evidence of reasons for/
against OAC prescription other than use of a guideline.
Identified Reasons for not Prescribing Oral
Anticoagulant
We identified one visit in which the provider referenced
Western Journal of Emergency Medicine

the patient’s inability to follow up as an outpatient as a
reason to support OAC prescription in the ED. Reasons
against OAC prescription included low stroke risk (n=17),
advanced age (n=4), lack of primary care physician
management and/or follow-up (n=4), and “other” reasons
(n=21). In patients perceived to be low stroke risk by the
provider, 64.7% (11/17) were classified as low stroke risk
by CHA2DS2-VASc. The most common “other” reason cited
was that the patient was already taking aspirin (n=7).
Oral Anticoagulant Prescribing Patterns
To evaluate changes in OAC prescribing patterns over
time, we compared the types of OACs prescribed stratified
by year in which the ED visit occurred (Appendix Table A5).
There was no variation in warfarin vs NOAC prescriptions
provided throughout the study period.
DISCUSSION
In this study, we found that less than a quarter (15.3%)
of OAC-naive AF patients at high risk for stroke and low
risk for bleeding received a new prescription of warfarin
or NOAC for stroke prophylaxis at the time of ED home
discharge. This is consistent with findings from a previous
study.26 Reasons for underutilization of OACs by emergency
physicians for AF management are likely multifactorial.27-30
A recent qualitative study by our group found that physicians
were uncomfortable with prescribing and had a sense of
futility in prescribing due to concerns that included low
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Table 3. Factors associated with the provision of oral anticoagulant
prescription at ED home discharge to 67 (48.2%) of 138 OAC-naive
AF patients.
Characteristic
Gender, Female

OR (95% CI)

P-value

2.9 (1.0-8.5)

0.05

1.9 (0.7-5.7)

0.21

CHA2DS2-VASc stratification
High risk
Low/intermediate risk

referent

Cardiology consultation
12.5 (1.5-100.5)
< 0.01
Significant values are bolded.
OR, odds ratio; CI, confidence interval; AF, atrial fibrillation.

adherence rates by patients prescribed anticoagulation and
bleeding risks associated with anticoagulation,31 which are
further magnified by an emergency physician’s inability to
follow up with patients.
A longitudinal cohort study of United States and
Canadian patients with new-onset AF found that use of
warfarin decreased from 65% at study enrollment to 44%
30 months later.29 However, Atzema et al demonstrated
that patients who received a prescription for warfarin in the
ED had a higher frequency of long-term warfarin use than
patients who were referred to another provider for OAC
management.32 This suggests that there is longitudinal value
in the initiation of a prescription associated with a significant
event—an acute care encounter—and that more resources
should be directed toward the initial acquisition of the
medication for the patient. One potential solution by Barrett
et al is the “provision of a protective tail of stroke prevention
for a limited duration until they can follow up.”33
Interestingly, 10.9% (n = 6/55) of patients were overprescribed OACs when they had a low stroke risk. This may
be driven in part by the increased frequency of cardioversion
attempted in this group (50% vs 7%), as anticoagulation is
often continued for four weeks after electrical cardioversion
and recommended by the American Heart Assocation.15 We
also found that these patients were more likely to be younger,
female, and have private or commercial insurance. However,
these findings contradict those from a study of the Practice
Innovation and Clinical Excellence (PINNACLE) Registry,
which found that older age, male gender, and Medicare
insurance were associated with increased likelihood of OAC
prescription among AF patients with a CHA2DS2-VASc score
of 0.34 The reason for this discrepancy is unclear, although
our small sample size of six patients limits our ability to
draw a statistically meaningful conclusion.
We found that cardiology consultation was a predictor
of whether or not OAC-naive patients were prescribed
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an OAC on home discharge. These findings are in
accordance with recently-published data from the nonoral vitamin K inhibitor era.35 Similarly, the TREAT-AF
study found significant, specialty-dependent differences in
anticoagulation use, with cardiologists being more likely
to prescribe OACs than primary care physicians.36 This is
likely due to provider comfort and familiarity with OAC
prescribing. Additionally, having a cardiology consult may
overcome barriers to outpatient follow-up as it directly
connects the patient with a follow-up provider. Concern
regarding lack of follow-up has been previously identified
as a barrier to OAC prescription in the ED,31 and a lack
of follow-up after ED discharge has been associated with
increased mortality in AF patients.26,30,37
However, we also found that ED providers did not
always abide by cardiology’s recommendations regarding
OAC management, as management in the ED was
incongruent with cardiology’s recommendations for 12 of
89 (13.5%) patients who received a cardiology consult.
Although ED providers did not provide reasons for these
discrepancies, patients who did not receive an OAC
prescription, despite cardiology’s recommendations, were
more likely to have a high-risk HAS-BLED score. While
our simplified outcome maximized benefit and minimized
harm (high stroke risk and low bleeding risk), we must
acknowledge that a high bleeding-risk score does not
preclude patients from being on OACs, and in fact, may still
be indicated as the two risk scores share many features.
It is important to note that cardiology consults occurred
in roughly two-thirds of encounters in our study population.
This is higher than cardiology consults obtained in nonacademic settings, with a recent study of Northern California
Kaiser Permanente AF patients showing that cardiology was
consulted 37.5% of the time.35 This reinforces the importance
of improving emergency physician comfort with OAC
prescribing independently of cardiology consultation.
Despite the fact that CHA2DS2-VASc and HAS-BLED
risk scores are well-validated tools in the AF population,
we found that they did not influence OAC prescribing.
This reflects findings from a previous study that found
only a modest correlation between CHADS2 score and
warfarin prescribing in an elderly AF population.38 This
may be because emergency physicians underutilize the
tools (potentially due to unawareness of the guidelines),
or because they overvalue the risk of adverse events (eg,
major bleeding events) when considering OAC initiation.
However, a recent multicenter prospective cohort study in
Spain showed that anticoagulation initiated in the ED for
AF patients with high stroke risk was not associated with an
increase in major bleeding event by one year and was in fact
associated with a decrease in mortality.39
We reviewed the reasons documented by physicians
either for or against OAC prescription and found that use of
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a guideline was cited in only 20.3% of visits. This finding
may suggest physicians’ unfamiliarity with risk-stratification
tools not specifically intended for ED populations. A
recent study reflected similar results, finding that among
1200 patients hospitalized at a community teaching
institution with documented AF, only 14% had a CHA2DS2VASc score documented in their charts.13,40 Those with a
documented score were significantly more likely to have
appropriate anticoagulation therapy, regardless of rate or
rhythm control.13,40 Expanded efforts to educate emergency
physicians on the use of these clinical decision-making tools
may improve comfort with prescribing OACs, and thus
improve time to appropriate anticoagulation.
This study contributes to the literature base describing
NOAC-era ED prescribing practices for AF in OAC-naive
patients.26,35 ED studies were limited to the use of warfarin
until recently, but also show inappropriately low rates of
OAC provision at ED discharge, ranging from less than
one-quarter to nearly one-half of patients deemed eligible
by calculation of stroke and bleeding risks.26,32,35,41 The
number of patients prescribed NOACs is rapidly increasing,
and it is critical to understand how this can inform clinical
recommendations specific to the ED setting.24,42 Because our
study took place over two years, we were able to evaluate
changes in the rate of NOAC prescriptions over time and
did not observe a significant change (Appendix Table A5).
This is supported by a recent study showing the use of
NOACs gradually increased over a three-year span (20122014); however, the use of warfarin was still 10-50 times
more common than dabigatran, rivaroxaban, and apixaban
as of 2015.43 In part, this may be due to challenges of
prescribing NOACs from the ED as they often require prior
authorization from a patient’s insurance.
Our work has again demonstrated an ED prescribing
practice gap for anticoagulants in patients with a primary
diagnosis of AF.26,32,35,41 However, it also showed that ED
providers initiate OAC prescribing that may be incongruent
with a cardiology consultation. Of note, while cardiology
consultations influenced prescribing, they did not always
correlate with the ED provider’s decision at the time of
discharge. The inconsistencies in OAC prescribing are likely
in part due to the lack of consensus guidelines for acute, EDspecific AF management, and has been previously noted in a
qualitative study interviewing providers who were concerned
about the lack of ED-specific guidelines as current guidelines
use data from outpatient, chronic care populations.14,31,44 With
no formal ED recommendations in place, it is not surprising that
more than half of patients with AF and high stroke risk do not
receive an OAC prescription at the time of home discharge.41
A lack of guideline utilization by providers may
include (1) wariness of using scoring tools that are not
specifically validated in ED populations; (2) hesitancy to
start aggressive anticoagulation therapy without definitive
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follow-up; (3) over-reliance on cardiology consultants; and
(4) lack of education regarding clinical decision-making
tools (CHA2DS2-VASc and HAS-BLED), as well as other
reasons.31 There is an opportunity to engage emergency
physicians to validate existing clinical algorithms for
AF management in ED populations. Systems-specific
interventions and electronic clinical decision support could
include improved methods for establishing outpatient followup after ED evaluation. These are several of many ways
emergency clinicians can be empowered to contribute to
multidisciplinary efforts to prevent strokes in patients with
high-risk AF.45
LIMITATIONS
Patients were included only if they had a primary ED
diagnosis of AF, and therefore the conclusions from this
study may not be applicable to patients with a different
primary diagnosis accompanied by AF (e.g., a patient with
pneumonia noted to have incidental AF). Patients with
related diagnoses such as atrial flutter were not included. The
degree of valvular disease was not abstracted. In addition, we
included only patients who were discharged home from the
ED. As a result, our patient population may have reflected
patients with lower stroke and/or bleeding risk (determined
by CHADS2, CHA2DS2-VASc, and HAS-BLED tools), fewer
co-morbidities, and a more favorable disposition status.
This retrospective study is limited to one academic,
tertiary care, urban hospital and our results may be
influenced by regional and/or institution-specific practice
patterns, and our analysis is limited by what was available
in the EHR. Prospective validation and external validation at
other EDs is needed.
CONCLUSION
Our study suggests that current risk stratification tools
for AF management are ineffectively used in the ED.
Cardiology consultation and female sex were the only
variables associated with OAC prescription at discharge.
This may be explained by ED providers’ unfamiliarity
with risk-stratification tools, lack of comfort with OAC
prescribing, or inability to facilitate patient follow-up. Clear
guidelines for ED providers are critical in this high-risk and
undertreated population. Possible solutions include new
algorithms, expanded educational dissemination of existing
guidelines, or collaborating with cardiology departments
to create protocols for initiation of anticoagulation by ED
providers coupled with automatic and timely outpatient
follow-up for longitudinal management.
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